Benjamin is Director of Cell Therapy Operations at Takeda in Lexington, Massachusetts, responsible for the manufacturing & supply readiness of Takeda’s cell therapy program at the Lexington site. This strategic program involves the commercial readiness of a genetically modified NK cell platform for the treatment of cancer.
Benjamin is a biopharmaceutical leader with 15 years of experience in the pharmaceutical industry across multiple disciplines and background in pharmaceutical operations, program management, and business excellence. He is experienced across a variety of technology platforms and modalities including solid dose, biologics, and cell & gene therapies.
Born and raised in Berlin, Germany, Benjamin has a degree in Pharmacy from Freie Universitaet Berlin. He joined Takeda in 2008.